Screening and diagnosis of sarcopenia in rheumatic and musculoskeletal diseases: findings from a cross-sectional study

• DOI: 10.1007/s00296-025-05821-7
• Publication Date: 2025-02-28T04:47:01Z
• Authors: Eleni C. Pardali; Katerina-Maria Ko...; Arriana Gkouvi; Irene A. Tsakmaki; Eleni Patrikiou; Maria Karapli; Christos Liaskos; Nektarios Marios ...; Vasiliki Syrmou; Ioannis Alexiou; Theodora Simopoulou; Sousana K. Papado...; Christina G. Kats...; Efterpi Zafiriou; Dimitrios G. Goulis; Dimitrios P. Bogd...; Maria G. Grammati...
• Keywords: Sarcopenic obesity; Cross-sectional study; Univariate analysis

Abstract Sarcopenia is characterized by loss of muscle mass and reduced function, presenting various adverse events, especially when inflammation present. The present study aimed to determine the prevalence sarcopenia sarcopenic obesity among patients with rheumatic musculoskeletal diseases (RMDs) identify risk for using two screening tools Strength, assistance walking, rising from a chair, climbing stairs, falls (SARC-F) Mini Risk Assessment (MSRA). In this single-center cross-sectional study, 220 consecutive visiting Department Rheumatology Clinical Immunology at University General Hospital Larissa were interviewed. EWGSOP criteria used diagnosis sarcopenia, while sensitivity, specificity, positive predictive values, number needed screen, negative likelihood ratios validate diagnostic validity SARC-F MSRA. Univariate multivariate logistic regression analyses also applied model relationship between other variables. total sample, 15.9% diagnosed one patient obesity. (sensitivity 22.2%, specificity 75.6%), 5-item 88.9%, 18.9%), 7-item MSRA 91.7%, 9.2%) presented poor clinical performance alone. showed that underweight status, systemic sclerosis appetite are strong contributors diagnosis. prevalent RMDs, essential within RMD clinics. None (SARC-F MSRA) can stand alone in assessing RMDs. More research required understand RMDs wide-using tools.